Dose2- 22Jul2021: Dose1 22Mar2021; Dizziness; short of breath; cognitive impairment; smelling things that weren't there; headache; blurred vision; uncontrollable shaking; balance issues; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 46 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 22Jul2021 17:00 (Batch/Lot number: unknown) at the age of 46 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Long Covid" (unspecified if ongoing). Concomitant medication(s) included: PROZAC; GABAPENTIN; HYDROXIZINE. Past drug history included: Morphine, reaction(s): "Known allergy: Morphine.", notes: Known allergy: Morphine. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: Unknown. Not available/provided to reporter at the time of report completion, Location of injection: Arm Left, Vaccine Administration Time: 12:00 PM), administration date: 22Mar2021, when the patient was 46 years old, for COVID-19 Immunization. The following information was reported: DIZZINESS (non-serious) with onset 22Jul2021, outcome "recovered with sequelae", described as "Dizziness"; DYSPNOEA (non-serious) with onset 22Jul2021, outcome "recovered with sequelae", described as "short of breath"; COGNITIVE DISORDER (non-serious) with onset 22Jul2021, outcome "recovered with sequelae", described as "cognitive impairment"; PAROSMIA (non-serious) with onset 22Jul2021, outcome "recovered with sequelae", described as "smelling things that weren't there"; HEADACHE (non-serious) with onset 22Jul2021, outcome "recovered with sequelae", described as "headache"; VISION BLURRED (non-serious) with onset 22Jul2021, outcome "recovered with sequelae", described as "blurred vision"; TREMOR (non-serious) with onset 22Jul2021, outcome "recovered with sequelae", described as "uncontrollable shaking"; BALANCE DISORDER (non-serious) with onset 22Jul2021, outcome "recovered with sequelae", described as "balance issues"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 22Jul2021 17:00, outcome "unknown", described as "Dose2- 22Jul2021: Dose1 22Mar2021". The events "dizziness", "short of breath", "cognitive impairment", "smelling things that weren't there", "headache", "blurred vision", "uncontrollable shaking" and "balance issues" were evaluated at the emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of dizziness, dyspnoea, cognitive disorder, parosmia, headache, vision blurred, tremor, balance disorder.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received concomitant medications within 2 weeks of vaccination. Ae resulted in emergency room/department or urgent treatment center. Ae treatment: CAT scan, monitoring, medicine for nausea. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19.  The lot number for bnt162b2 was not provided and will be requested during follow up.